TP53 and non-small cell lung carcinoma: Since TP53 mutations are present in the majority of NSCLC cases (Deben et al., 2016), some studies suggest that Nutlin-3a can drive TP53 wild-type AOs into senescence or apoptosis, thereby promoting the growth of PDLCOs with TP53 mutations.